Nucleix Ltd.

Nucleix Ltd. is a biotechnology startup, founded in 2008 and headquartered in Israel. The company is dedicated to revolutionizing cancer treatment through early disease detection, utilizing NGS-based and PCR-based technology to identify methylation changes. Their flagship product, EpiCheck®, is a non-invasive testing approach for early-stage and recurrent cancer detection, providing highly accurate and sensitive results. With their Bladder EpiCheck® kit already CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States, Nucleix is making strides in advancing cancer diagnostics. Their ongoing efforts include the commercialization of the Lung EpiCheck® test for high-risk individuals, as well as evaluating additional tests for other high-risk diseases. Notably, Nucleix recently secured a significant $22.00M Venture Round investment on 05 January 2022, with backing from prominent investors including RA Capital Management, OrbiMed, Sands Capital Ventures, and Zohar Zisapel. This investment underscores the confidence of the financial community in Nucleix's approach and technology, positioning the company for further growth and impact in the biotechnology and healthcare industries.